The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 03 2022
30 03 2022
Historique:
received:
18
10
2021
accepted:
23
03
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Regulatory T cells (Tregs) suppress the host immune response and maintain immune homeostasis. Tregs also promote cancer progression and are involved in resistance to immune checkpoint inhibitor treatments. Recent studies identified selective CCR8 expression on tumor-infiltrating Tregs; CCR8+ Tregs have been indicated as a possible new target of cancer immunotherapy. Here, we investigated the features of CCR8+ Tregs in lung cancer patients. CCR8+ Tregs were highly activated and infiltration of CCR8+ Tregs in tumors was associated with poor prognosis in lung cancer patients. We also investigated their immune suppressive function, especially the influence on cytotoxic T lymphocyte cell function. The Cancer Genome Atlas analysis revealed that CD8 T cell activities were suppressed in high CCR8-expressing tumors. Additionally, depletion of CCR8+ cells enhanced CD8 T cell function in an ex vivo culture of lung tumor-infiltrating cells. Moreover, CCR8+ Tregs, but not CCR8- Tregs, induced from human PBMCs markedly suppressed CD8 T cell cytotoxicity. Finally, we demonstrated the therapeutic effect of targeting CCR8 in a murine model of lung cancer. These findings reveal the significance of CCR8+ Tregs for immunosuppression in lung cancer, especially via cytotoxic T lymphocyte cell suppression, and suggest the potential value of CCR8-targeted therapy for cancer treatment.
Identifiants
pubmed: 35354899
doi: 10.1038/s41598-022-09458-5
pii: 10.1038/s41598-022-09458-5
pmc: PMC8967908
doi:
Substances chimiques
CCR8 protein, human
0
Ccr8 protein, mouse
0
Receptors, CCR8
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5377Informations de copyright
© 2022. The Author(s).
Références
J Clin Med. 2020 May 06;9(5):
pubmed: 32384677
J Immunol. 1999 Nov 15;163(10):5211-8
pubmed: 10553041
Cancer Sci. 2019 Jul;110(7):2080-2089
pubmed: 31102428
Cancer Res. 2021 Jun 1;81(11):2983-2994
pubmed: 33757978
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Clin Cancer Res. 2015 Oct 1;21(19):4327-36
pubmed: 26429981
Proc Natl Acad Sci U S A. 2022 Feb 15;119(7):
pubmed: 35140181
J Exp Med. 2013 Sep 23;210(10):1889-98
pubmed: 23999500
Immunity. 2016 Nov 15;45(5):1135-1147
pubmed: 27851914
Expert Opin Ther Targets. 2018 Apr;22(4):353-363
pubmed: 29532697
Cancer Res. 2018 Sep 15;78(18):5340-5348
pubmed: 30026324
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Int Immunol. 2016 Aug;28(8):401-9
pubmed: 27160722
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50
pubmed: 24127572
J Allergy Clin Immunol. 2005 Nov;116(5):949-59; quiz 960
pubmed: 16275360
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Cancer Immunol Immunother. 2020 Sep;69(9):1855-1867
pubmed: 32367308
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Cancer Immunol Immunother. 2005 Aug;54(8):721-8
pubmed: 16010587
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Int Immunol. 2020 May 30;32(6):397-405
pubmed: 32009163
Immunity. 2016 Nov 15;45(5):1122-1134
pubmed: 27851913
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Immunity. 2016 May 17;44(5):989-1004
pubmed: 27192565
Curr Opin Immunol. 2014 Apr;27:1-7
pubmed: 24413387
FEBS J. 2018 Aug;285(16):2944-2971
pubmed: 29637711
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Lancet Oncol. 2015 Apr;16(4):e165-72
pubmed: 25846096
Biomed Pharmacother. 2020 Jul;127:109996
pubmed: 32388240
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33589525